Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

被引：9
|
作者：
Nagel, Sylke [3 ]
Califano, Raffaele [2 ]
Thatcher, Nicholas [1 ]
Blackhall, Fiona [1 ]
机构：
[1] Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England
[2] Osped Santa Maria Misericordia, SC Oncol Med, I-06120 Perugia, Italy
[3] Martha Maria Hosp, D-06120 Halle, Germany
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2007年 / 8卷 / 18期
关键词：
carboplatin; chemotherapy; gemcitabine; non-small-cell lung cancer;
D O I：
10.1517/14656566.8.18.3265
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent, gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile. Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.
引用
收藏
页码：3265 / 3275
页数：11
相关论文
共 50 条
  • [41] Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer
    Hirose, T
    Horichi, N
    Ohmori, T
    Shirai, T
    Sohma, S
    Yamaoka, T
    Ohnishi, T
    Adachi, M
    LUNG CANCER, 2003, 39 (01) : 91 - 97
  • [42] Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer
    Takayama, Koichi
    Ichiki, Masao
    Matsumoto, Takemasa
    Ebi, Noriyuki
    Akamine, Shinji
    Tokunaga, Shoji
    Yamada, Tadaaki
    Uchino, Junji
    Nakanishi, Yoichi
    ONCOLOGIST, 2020, 25 (03) : 208 - +
  • [43] State-of-the art treatment of locally advanced and metastatic non-small cell lung cancer
    Bunn, PA
    ANTI-CANCER DRUGS, 2001, 12 : S3 - S8
  • [44] Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer
    Takeda, K
    Takifuji, N
    Uejima, H
    Yoshimura, N
    Terakawa, K
    Negoro, S
    LUNG CANCER, 2002, 38 (03) : 303 - 308
  • [45] Cisplatin-carboplatin-gemcitabine or ifosfamide-gemcitabine in advanced non-small cell lung carcinoma: Two pilot studies
    Berghmans, T
    Klastersky, J
    Markiewicz, E
    Mommen, P
    Sculier, JP
    ANTICANCER RESEARCH, 1999, 19 (6C) : 5651 - 5655
  • [46] The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer
    Cullen, M
    LUNG CANCER, 2005, 50 : S5 - S7
  • [47] Efficacy and feasibility of gemcitabine and carboplatin as first-line chemotherapy in elderly patients with advanced non-small cell lung cancer
    Lim, Kyu-Hyoung
    Lee, Hui-Young
    Song, Seo-Young
    CHINESE MEDICAL JOURNAL, 2013, 126 (24) : 4644 - 4648
  • [48] Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell Lung Cancer
    Jahnke, Kristoph
    Keilholz, Ulrich
    Lueftner, Diana
    Thiel, Eckhard
    Schmittel, Alexander
    ANTICANCER RESEARCH, 2011, 31 (01) : 317 - 323
  • [49] Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
    Cohen, Martin H.
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2009, 14 (09) : 930 - 935
  • [50] Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy
    Novello, S
    Kielhorn, A
    Stynes, G
    Selvaggi, G
    De Marinis, F
    Maestri, A
    Foggi, P
    Tilden, D
    Tonato, M
    Crinò, L
    Rinaldi, M
    Migliorino, AM
    Scagliotti, GV
    LUNG CANCER, 2005, 48 (03) : 379 - 387
12345